{"title":"47例小儿Blau综合征的远期预后分析","authors":"Xinwei Shi, Jianghong Deng, Junmei Zhang, Xiaozhen Zhao, Yinan Zhao, Li Li, Fengqiao Gao, Weiying Kuang, Jiang Wang, Xiaohua Tan, Chao Li, Shipeng Li, Caifeng Li","doi":"10.1186/s12887-025-05584-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Blau syndrome (BS) is a rare autoinflammatory disease characterized by a clinical triad of uveitis, dermatitis and arthritis. The aim of our study was to summarize organ involvement, predict disease prognosis and evaluate treatment response.</p><p><strong>Methods: </strong>Clinical data of 47 Chinese children who were diagnosed with Blau syndrome in Beijing Children's hospital, Capital Medical University was retrospectively analyzed. Direct sequencing of NOD2 gene was performed by sanger sequencing. Data were analyzed through SPSS 21.0. A Bayesian network was constructed to integrate prediction algorithms of genetic mutations and clinical manifestations, exploring the complex relationship between genotype and phenotype through R (Version 4.4.1, R Core Development Team). P value < 0.05 was significant.</p><p><strong>Results: </strong>The 47 patients included 26 males and 21 females. Median age of disease onset was 13.64 months, ranging from 1 to 51 months. At baseline, incidence of fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%. Nearly 30% patients (14 patients) presented with characteristic triad. Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively. Inflammatory indices (e.g., erythrocyte sedimentation rate and C reactive protein) were above normal range. Twelve different NOD2 mutations were identified. R334Q was associated with arthritis, rash, uveitis and fever, whereas R334W was associated with arthritis, rash and fever. Approximately 95.7% patients (45 patients) were treated with combination of prednisolone and methotrexate and 42.6% patients (20 patients) were treated with tumor necrosis factor inhibitors. At the most recent follow-up visit, 34 patients (72.3%) achieved disease control. Patients treated with TNF-α inhibitors had a higher remission rate.</p><p><strong>Conclusions: </strong>Clinical manifestations of Blau syndrome in this study were various. TNF-α inhibitors were effective in inducing remission rate of Blau syndrome.</p>","PeriodicalId":9144,"journal":{"name":"BMC Pediatrics","volume":"25 1","pages":"374"},"PeriodicalIF":2.0000,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12066035/pdf/","citationCount":"0","resultStr":"{\"title\":\"Long-term prognosis of 47 pediatric patients with Blau syndrome in China.\",\"authors\":\"Xinwei Shi, Jianghong Deng, Junmei Zhang, Xiaozhen Zhao, Yinan Zhao, Li Li, Fengqiao Gao, Weiying Kuang, Jiang Wang, Xiaohua Tan, Chao Li, Shipeng Li, Caifeng Li\",\"doi\":\"10.1186/s12887-025-05584-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Blau syndrome (BS) is a rare autoinflammatory disease characterized by a clinical triad of uveitis, dermatitis and arthritis. The aim of our study was to summarize organ involvement, predict disease prognosis and evaluate treatment response.</p><p><strong>Methods: </strong>Clinical data of 47 Chinese children who were diagnosed with Blau syndrome in Beijing Children's hospital, Capital Medical University was retrospectively analyzed. Direct sequencing of NOD2 gene was performed by sanger sequencing. Data were analyzed through SPSS 21.0. A Bayesian network was constructed to integrate prediction algorithms of genetic mutations and clinical manifestations, exploring the complex relationship between genotype and phenotype through R (Version 4.4.1, R Core Development Team). P value < 0.05 was significant.</p><p><strong>Results: </strong>The 47 patients included 26 males and 21 females. Median age of disease onset was 13.64 months, ranging from 1 to 51 months. At baseline, incidence of fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%. Nearly 30% patients (14 patients) presented with characteristic triad. Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively. Inflammatory indices (e.g., erythrocyte sedimentation rate and C reactive protein) were above normal range. Twelve different NOD2 mutations were identified. R334Q was associated with arthritis, rash, uveitis and fever, whereas R334W was associated with arthritis, rash and fever. Approximately 95.7% patients (45 patients) were treated with combination of prednisolone and methotrexate and 42.6% patients (20 patients) were treated with tumor necrosis factor inhibitors. At the most recent follow-up visit, 34 patients (72.3%) achieved disease control. Patients treated with TNF-α inhibitors had a higher remission rate.</p><p><strong>Conclusions: </strong>Clinical manifestations of Blau syndrome in this study were various. TNF-α inhibitors were effective in inducing remission rate of Blau syndrome.</p>\",\"PeriodicalId\":9144,\"journal\":{\"name\":\"BMC Pediatrics\",\"volume\":\"25 1\",\"pages\":\"374\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-05-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12066035/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Pediatrics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12887-025-05584-x\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12887-025-05584-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
摘要
目的:Blau综合征(BS)是一种罕见的自身炎症性疾病,临床表现为葡萄膜炎、皮炎和关节炎。本研究的目的是总结器官受累情况,预测疾病预后和评估治疗反应。方法:回顾性分析首都医科大学附属北京儿童医院诊断为Blau综合征的47例中国儿童的临床资料。采用sanger测序对NOD2基因进行直接测序。数据采用SPSS 21.0进行分析。构建贝叶斯网络,整合基因突变与临床表现的预测算法,通过R (Version 4.4.1, R Core Development Team)探索基因型与表型之间的复杂关系。结果:47例患者中男性26例,女性21例。发病年龄中位数为13.64个月,范围为1 ~ 51个月。基线时,发热、关节炎、皮疹、皮炎和葡萄膜炎的发生率分别为34%、93.6%、72.3%和31.9%。近30%(14例)患者表现为特征性三联征。血管炎和肺间质性疾病的发生率分别为27.7%和17.0%。炎症指标(如红细胞沉降率和C反应蛋白)高于正常范围。鉴定出12种不同的NOD2突变。R334Q与关节炎、皮疹、葡萄膜炎和发热相关,而R334W与关节炎、皮疹和发热相关。大约95.7%的患者(45例)使用强的松龙和甲氨蝶呤联合治疗,42.6%的患者(20例)使用肿瘤坏死因子抑制剂治疗。在最近一次随访中,34例患者(72.3%)实现了疾病控制。接受TNF-α抑制剂治疗的患者有更高的缓解率。结论:本研究中Blau综合征的临床表现多样。TNF-α抑制剂能有效诱导Blau综合征的缓解率。
Long-term prognosis of 47 pediatric patients with Blau syndrome in China.
Objectives: Blau syndrome (BS) is a rare autoinflammatory disease characterized by a clinical triad of uveitis, dermatitis and arthritis. The aim of our study was to summarize organ involvement, predict disease prognosis and evaluate treatment response.
Methods: Clinical data of 47 Chinese children who were diagnosed with Blau syndrome in Beijing Children's hospital, Capital Medical University was retrospectively analyzed. Direct sequencing of NOD2 gene was performed by sanger sequencing. Data were analyzed through SPSS 21.0. A Bayesian network was constructed to integrate prediction algorithms of genetic mutations and clinical manifestations, exploring the complex relationship between genotype and phenotype through R (Version 4.4.1, R Core Development Team). P value < 0.05 was significant.
Results: The 47 patients included 26 males and 21 females. Median age of disease onset was 13.64 months, ranging from 1 to 51 months. At baseline, incidence of fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%. Nearly 30% patients (14 patients) presented with characteristic triad. Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively. Inflammatory indices (e.g., erythrocyte sedimentation rate and C reactive protein) were above normal range. Twelve different NOD2 mutations were identified. R334Q was associated with arthritis, rash, uveitis and fever, whereas R334W was associated with arthritis, rash and fever. Approximately 95.7% patients (45 patients) were treated with combination of prednisolone and methotrexate and 42.6% patients (20 patients) were treated with tumor necrosis factor inhibitors. At the most recent follow-up visit, 34 patients (72.3%) achieved disease control. Patients treated with TNF-α inhibitors had a higher remission rate.
Conclusions: Clinical manifestations of Blau syndrome in this study were various. TNF-α inhibitors were effective in inducing remission rate of Blau syndrome.
期刊介绍:
BMC Pediatrics is an open access journal publishing peer-reviewed research articles in all aspects of health care in neonates, children and adolescents, as well as related molecular genetics, pathophysiology, and epidemiology.